-
Though valuations are at a premium, the company has strong earnings prospects ahead
-
Though the management mentions that Cenexi has a decent clientele and the order book can be leveraged, an investment of 30 million euros is needed for its revamp
-
Ami Organics is making its mark in the niche segments of chemicals having applications in lithium-ion batteries and semiconductors.
-
On World Cancer Day today, a conversation with Dr Sewanti Limaye, Director, Precision Oncology, HN Reliance Hospital and Research Centre, on the new frontiers of cancer treatment in India.
-
The oncology market in India is estimated to grow by $734.18 million in 2025, growing at a CAGR of over 13 percent. With progress in faster and less expensive gene sequencing, precision medicine is starting to be used more often, most notably in the treatment of lung cancer, says Amitabh Dube.
-
While the respiratory portfolio remains a significant part of the US portfolio, the peptides portfolio is a key watch in the near to medium term.
-
EMs are expected to remain the chief driver of top-line growth, driven by chronic therapies and biosimilars
-
The IPO consists of a pure offer for sale of upto 21.68 million shares by its existing promoters and shareholders.
-
The company, which was launched in 2016, plans to use the funds to expand into other single-specialty areas, including diagnostics
-
Medicamen Biotech plans to go for domestic launch of oncology formulations from January 2022, in sync with API supply from Shivalik Rasayan. This is the key near-term trigger.
-
In order to address the opportunities in oncology, peptides and iron compounds, Glenmark Life Science plans to build an R&D pipeline in the coming years
-
-
The new centers have ramped up quickly to breakeven EBITDA positive, said BS Ajaikumar, Chairman & CEO, Healthcare Global Enterprises.
-
In an interview to CNBC-TV18, Himanshu Baid, MD of Poly Medicure said that they are investing in new plant in Haryana in the field of nephrology.
-
The company is aiming for at least one outlicensing deal in the next year and Saldanha also feels pharma giant will grow at a 15-20 percent CAGR over the next five years.
-
Selexys specialises in sickle cell disease, an inherited form of anaemia that is most common among people of African descent.
-
Have robust expansion plans and would have 26 oncology centers by end of FY18 from the current 17 centers, said BS Ajaikumar, Chairman and CEO, Healthcare Global Enterprises.
-
Acacia manufacturing unit currently manufactures advanced intermediates of potent APIs useful to the company's business as well as for supply to third-party customers
-
During the audit of Sun Pharma's Active Pharma Ingredients plant in Ahmednagar by US FDA, minor compliance observations were noted, which won't impact the facility adversely.
-
Apart from Europe, Ochoa Laboratories currently has operations in Uganda, Venezuala and Costa Rica among other Latin American and African countries. Dr Datsons Labs shares were trading 2.99 percent down at Rs 7.80 apiece during pre-close session on the BSE.
-
Investors lapped up more shares of Shilpa Medicare on Wednesday after the US Food and Drug Administration (US FDA) has inspected 2 manufacturing units at Raichur. The stock hit a life high of Rs 1,018.50, up 10 percent intraday.
-
Vishnukant Bhutada, MD, Shilpa Medicare said sales was low due to expansion and R&D work. He added that the past expansions will start reaping benefits from this year onwards.
-
The multi-layered deal involves UK-based GlaxoSmithKline (GSK) acquiring the Swiss major's vaccine business, while the latter would purchase GSK's cancer drugs portfolio.
-
GE's Discovery IQ PET/CT with its advanced features promises to be a landmark in cancer detection and care. It is upgradable, scalable and has outstanding image quality. Discovery IQ PET/CT can perform more number of scans in a day and each scan takes considerably less time.
-
Dr. RV Parameswaran, Head of Nuclear Medicine at Manipal Hospital, speaks about how important it is in a country like India to develop oncology solutions that are high on performance, but at the same time affordable
